New Studies Question Utility of Gene Expression Testing for Cancers With Unknown Primary Site, Low-Risk Breast Cancer

 Email not displaying correctly? View it in your browser.
  Lab and Pathology Insider Logo  
February 26, 2019  
placeholder TESTING STRATEGY
New Studies Question Utility of Gene Expression Testing for Cancers With Unknown Primary Site, Low-Risk Breast Cancer
From - Diagnostic Testing & Emerging Technologies
The alarming finding that a person is now more statistically likely to die of an opioid overdose than a motor vehicle crash comes from…
Read More
placeholder COMPLIANCE PERSPECTIVES
Compliance Perspectives: CMS Reviews PAMA Reporting Basics for Hospital Outreach Labs
From - Lab Compliance Advisor
PAMA reporting is tricky business in which mistakes and omissions carry the risk of civil monetary penalties of up to $10,000 per day. So, whether you're with…
Read More
placeholder NEWS
Medical Marijuana: CBD Doesn't Get You "High" But May Make You Fail a Drug Test
From - National Intelligence Report
Testing for marijuana isn't as simple as it used to be thanks to the increased use of cannabidiol (CBD) products. Based on oils extracted from…
Read More
placeholder INDUSTRY BUZZ
FDA Watch: Agency Finalizes New Medical Device Marketing Pathway & Okays Direct Lab Reporting of PGx Test Results
From - Laboratory Industry Report
On Jan. 22, the FDA issued final guidance establishing a new alternative pathway for getting medical devices to…
Read More

For questions concerning delivery of this email, please contact customer service at:
(888) 729-2315 | customerservice@plainlanguagemedia.com

Copyright © 2019, All rights reserved.
Plain Language Media LLLP
PO Box 509, New London, CT 06320